NBC Securities Inc. Invests $336,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

NBC Securities Inc. acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,099 shares of the company’s stock, valued at approximately $336,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. Miller Howard Investments Inc. NY increased its position in shares of Medpace by 1.3% during the fourth quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock worth $943,000 after acquiring an additional 39 shares during the period. Schulhoff & Co. Inc. raised its position in Medpace by 2.0% during the 3rd quarter. Schulhoff & Co. Inc. now owns 2,250 shares of the company’s stock valued at $545,000 after purchasing an additional 45 shares in the last quarter. Campbell Newman Asset Management Inc. grew its position in shares of Medpace by 0.4% during the 4th quarter. Campbell Newman Asset Management Inc. now owns 11,095 shares of the company’s stock worth $3,401,000 after buying an additional 46 shares in the last quarter. Treasurer of the State of North Carolina increased its stake in shares of Medpace by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 10,230 shares of the company’s stock valued at $2,477,000 after buying an additional 50 shares during the period. Finally, Sectoral Asset Management Inc. raised its holdings in shares of Medpace by 4.9% in the third quarter. Sectoral Asset Management Inc. now owns 1,181 shares of the company’s stock valued at $286,000 after acquiring an additional 55 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on MEDP. StockNews.com upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and upped their target price for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. Guggenheim lifted their price target on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 price objective for the company. Finally, Robert W. Baird lifted their target price on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $443.00.

View Our Latest Research Report on Medpace

Insider Buying and Selling

In other Medpace news, major shareholder Medpace Investors, Llc sold 13,988 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the sale, the insider now owns 5,525,959 shares in the company, valued at approximately $2,135,175,298.01. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Medpace news, CEO August J. Troendle sold 4,782 shares of the stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $400.58, for a total transaction of $1,915,573.56. Following the sale, the chief executive officer now directly owns 716,197 shares of the company’s stock, valued at approximately $286,894,194.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the completion of the transaction, the insider now directly owns 5,525,959 shares of the company’s stock, valued at approximately $2,135,175,298.01. The disclosure for this sale can be found here. Insiders sold 209,224 shares of company stock worth $84,618,441 in the last 90 days. Insiders own 20.30% of the company’s stock.

Medpace Stock Performance

Medpace stock opened at $398.52 on Wednesday. The stock has a market cap of $12.35 billion, a PE ratio of 40.62, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40. The stock has a 50-day moving average of $397.09 and a two-hundred day moving average of $339.13. Medpace Holdings, Inc. has a one year low of $197.39 and a one year high of $421.00.

Medpace (NASDAQ:MEDPGet Free Report) last released its earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. The company had revenue of $511.00 million during the quarter, compared to analysts’ expectations of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. Medpace’s revenue for the quarter was up 17.7% on a year-over-year basis. During the same period last year, the business earned $2.27 EPS. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 11.29 EPS for the current fiscal year.

Medpace Company Profile

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Further Reading

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPFree Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.